VDR and hyperphosphatemia: Paricalcitol has more selective activation of VDR in the parathyroid gland over that in the intestine and bone and offers the possibility of minimizing the risk of hypercalcemia and hyperphosphatemia, while still significantly reducing PTH [30, 38, 39].